- Home
- BBAR vs IMCR Comparison
BBAR vs IMCR Comparison
Compare BBAR & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBAR
- IMCR
- Stock Information
- Founded
- BBAR 1886
- IMCR 2008
- Country
- BBAR Argentina
- IMCR United Kingdom
- Employees
- BBAR N/A
- IMCR N/A
- Industry
- BBAR Commercial Banks
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BBAR Finance
- IMCR Health Care
- Exchange
- BBAR Nasdaq
- IMCR Nasdaq
- Market Cap
- BBAR 3.4B
- IMCR 1.6B
- IPO Year
- BBAR N/A
- IMCR 2021
- Fundamental
- Price
- BBAR $15.13
- IMCR $35.05
- Analyst Decision
- BBAR Buy
- IMCR Buy
- Analyst Count
- BBAR 1
- IMCR 10
- Target Price
- BBAR $27.00
- IMCR $58.13
- AVG Volume (30 Days)
- BBAR 693.2K
- IMCR 322.9K
- Earning Date
- BBAR 08-20-2025
- IMCR 08-07-2025
- Dividend Yield
- BBAR 3.39%
- IMCR N/A
- EPS Growth
- BBAR 9.91
- IMCR N/A
- EPS
- BBAR 0.57
- IMCR N/A
- Revenue
- BBAR $2,595,064,489.00
- IMCR $333,581,000.00
- Revenue This Year
- BBAR N/A
- IMCR $26.82
- Revenue Next Year
- BBAR $35.30
- IMCR $8.15
- P/E Ratio
- BBAR $8.73
- IMCR N/A
- Revenue Growth
- BBAR N/A
- IMCR 25.75
- 52 Week Low
- BBAR $7.05
- IMCR $23.15
- 52 Week High
- BBAR $25.01
- IMCR $41.54
- Technical
- Relative Strength Index (RSI)
- BBAR 36.31
- IMCR 58.09
- Support Level
- BBAR $14.12
- IMCR $32.20
- Resistance Level
- BBAR $16.59
- IMCR $35.69
- Average True Range (ATR)
- BBAR 0.71
- IMCR 1.29
- MACD
- BBAR -0.06
- IMCR 0.29
- Stochastic Oscillator
- BBAR 29.97
- IMCR 81.93
About BBAR Banco BBVA Argentina S.A. ADS
Banco BBVA Argentina SA is a banking services provider in Argentina. It provides financial assistance to large corporations, small and medium-sized companies, as well as individuals. It bank provides services through retail, corporate, investment banking, and Small and medium-sized companies divisions. Through the retail banking segment, it provides banking products and services to individuals, corporate banking deals with services to corporates, and the small and medium-sized companies segment focuses on foreign trade, agricultural business, and digital products.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.